日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study

一项针对复发或难治性急性髓系白血病患者或60岁以上新诊断急性髓系白血病患者的贝利司他（PXD101）II期研究：加州癌症联盟研究

期刊:Leukemia & Lymphoma
影响因子:2.2
doi:10.3109/10428194.2013.877134
Kirschbaum, Mark H; Foon, Kenneth A; Frankel, Paul; Ruel, Christopher; Pulone, Bernadette; Tuscano, Joseph M; Newman, Edward M
白血病
肿瘤免疫
肿瘤
发表日期：2014
文献求助 收藏

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma

伏立诺他治疗复发或难治性惰性非霍奇金淋巴瘤和套细胞淋巴瘤的II期研究

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2010.32.1398
Kirschbaum, Mark; Frankel, Paul; Popplewell, Leslie; Zain, Jasmine; Delioukina, Maria; Pullarkat, Vinod; Matsuoka, Deron; Pulone, Bernadette; Rotter, Arnold J; Espinoza-Delgado, Igor; Nademanee, Auayporn; Forman, Stephen J; Gandara, David; Newman, Edward
细胞生物学
淋巴瘤
发表日期：2011
文献求助 收藏